Bone Biologics Corp
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.6174
- Today's High:
- $0.6779
- Open Price:
- $0.6541
- 52W Low:
- $0.14
- 52W High:
- $1.97
- Prev. Close:
- $0.67
- Volume:
- 84655
Company Statistics
- Market Cap.:
- $3.31 million
- Book Value:
- 0.166
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -59.44%
- Return on Equity TTM:
- -102.26%
Company Profile
Bone Biologics Corp had its IPO on 2016-03-31 under the ticker symbol BBLG.
The company operates in the Healthcare sector and Medical Devices industry. Bone Biologics Corp has a staff strength of 2 employees.
Stock update
Shares of Bone Biologics Corp opened at $0.65 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.62 - $0.68, and closed at $0.64.
This is a -4.48% slip from the previous day's closing price.
A total volume of 84,655 shares were traded at the close of the day’s session.
In the last one week, shares of Bone Biologics Corp have slipped by -4.62%.
Bone Biologics Corp's Key Ratios
Bone Biologics Corp has a market cap of $3.31 million, indicating a price to book ratio of 0.9268 and a price to sales ratio of 0.
In the last 12-months Bone Biologics Corp’s revenue was $0 with a gross profit of $0 and an EBITDA of $-824964. The EBITDA ratio measures Bone Biologics Corp's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Bone Biologics Corp’s operating margin was 0% while its return on assets stood at -59.44% with a return of equity of -102.26%.
In Q1, Bone Biologics Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Bone Biologics Corp’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.33 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Bone Biologics Corp’s profitability.
Bone Biologics Corp stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -6.6371. Its price to sales ratio in the trailing 12-months stood at 0.
Bone Biologics Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $6.78 million
- Total Liabilities
- $4.01 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Bone Biologics Corp ended 2024 with $6.78 million in total assets and $0 in total liabilities. Its intangible assets were valued at $6.78 million while shareholder equity stood at $2.77 million.
Bone Biologics Corp ended 2024 with $0 in deferred long-term liabilities, $4.01 million in other current liabilities, 16701.00 in common stock, $-75670126.00 in retained earnings and $0 in goodwill. Its cash balance stood at $6.19 million and cash and short-term investments were $6.19 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Bone Biologics Corp’s total current assets stands at $6.78 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $0 and inventory worth $0.
In 2024, Bone Biologics Corp's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Bone Biologics Corp paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.64
- 52-Week High
- $1.97
- 52-Week Low
- $0.14
- Analyst Target Price
- $4.9
Bone Biologics Corp stock is currently trading at $0.64 per share. It touched a 52-week high of $1.97 and a 52-week low of $1.97. Analysts tracking the stock have a 12-month average target price of $4.9.
Its 50-day moving average was $1.11 and 200-day moving average was $5.64 The short ratio stood at 1.27 indicating a short percent outstanding of 0%.
Around 4014.3% of the company’s stock are held by insiders while 1831% are held by institutions.
Frequently Asked Questions About Bone Biologics Corp
Similar Industry Stocks (Medical Devices)
Most Active
Top Gainers
Top Losers
About
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company’s NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L2-S1. The company’s platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.